On 29oct2019 an email was received from the fda, mw5090302 with information received from an eye care provider (ecp) who reported a new patient (pt) presented with significant corneal and conjunctival inflammation, discomfort and reduced vision on (b)(6) 2019 while wearing an acuvue® oasys® brand contact lens.The pt was ¿over-wearing and misusing¿ the contact lenses and had not had an eye exam or contact lens evaluation in more than 10 years.The pts prior prescribing ecp retired 5 years ago and the office was closed.The pt continued to receive contact lenses from an on-line provider without a valid prescription or prescription verification from the on-line provider.The emergent office visit revealed corneal edema, corneal staining and corneal neovascularization.No additional medical information was provided.The lot number of the suspect product was not provided.Multiple attempts were made to the reporting ecp for additional medical and product information, but nothing additional has been provided.It is unknown if the suspect lens is available for return for evaluation.If any further relevant information is received, a supplemental report will be filed.
|